SI3125888T1 - 2,4-TIAZOLIDINDION DERIVATIVES FOR TREATMENT OF CENTRAL STYLE SYSTEM DISEASE - Google Patents
2,4-TIAZOLIDINDION DERIVATIVES FOR TREATMENT OF CENTRAL STYLE SYSTEM DISEASE Download PDFInfo
- Publication number
- SI3125888T1 SI3125888T1 SI201530325T SI201530325T SI3125888T1 SI 3125888 T1 SI3125888 T1 SI 3125888T1 SI 201530325 T SI201530325 T SI 201530325T SI 201530325 T SI201530325 T SI 201530325T SI 3125888 T1 SI3125888 T1 SI 3125888T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compounds
- mixture
- compound
- use according
- thiazolidine
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title claims 5
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical class O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 210000003169 central nervous system Anatomy 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 19
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- OXVFDZYQLGRLCD-YVEFUNNKSA-N (5r)-5-[[4-[2-[5-[(1s)-1-hydroxyethyl]pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC([C@@H](O)C)=CC=C1CCOC(C=C1)=CC=C1C[C@@H]1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-YVEFUNNKSA-N 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- OXVFDZYQLGRLCD-SJKOYZFVSA-N leriglitazone Chemical compound N1=CC([C@H](O)C)=CC=C1CCOC(C=C1)=CC=C1C[C@@H]1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-SJKOYZFVSA-N 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- OXVFDZYQLGRLCD-PXAZEXFGSA-N (5s)-5-[[4-[2-[5-[(1r)-1-hydroxyethyl]pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC([C@H](O)C)=CC=C1CCOC(C=C1)=CC=C1C[C@H]1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-PXAZEXFGSA-N 0.000 claims 2
- OXVFDZYQLGRLCD-SJCJKPOMSA-N (5s)-5-[[4-[2-[5-[(1s)-1-hydroxyethyl]pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC([C@@H](O)C)=CC=C1CCOC(C=C1)=CC=C1C[C@H]1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-SJCJKPOMSA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 201000010901 lateral sclerosis Diseases 0.000 claims 2
- 208000036546 leukodystrophy Diseases 0.000 claims 2
- 208000012268 mitochondrial disease Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010006542 Bulbar palsy Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 201000008152 organic acidemia Diseases 0.000 claims 1
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000000196 pseudobulbar palsy Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- OXVFDZYQLGRLCD-UHFFFAOYSA-N hydroxypioglitazone Chemical compound N1=CC(C(O)C)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 OXVFDZYQLGRLCD-UHFFFAOYSA-N 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382130 | 2014-04-02 | ||
| PCT/EP2015/057224 WO2015150476A1 (en) | 2014-04-02 | 2015-04-01 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| EP15713499.0A EP3125888B1 (en) | 2014-04-02 | 2015-04-01 | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3125888T1 true SI3125888T1 (en) | 2018-08-31 |
Family
ID=50513194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201530325T SI3125888T1 (en) | 2014-04-02 | 2015-04-01 | 2,4-TIAZOLIDINDION DERIVATIVES FOR TREATMENT OF CENTRAL STYLE SYSTEM DISEASE |
| SI201531591T SI3388064T1 (sl) | 2014-04-02 | 2015-04-01 | Derivati 2,4-tiazolidindiona pri zdravljenju motenj centralnega živčnega sistema |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201531591T SI3388064T1 (sl) | 2014-04-02 | 2015-04-01 | Derivati 2,4-tiazolidindiona pri zdravljenju motenj centralnega živčnega sistema |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9782395B2 (enExample) |
| EP (2) | EP3388064B1 (enExample) |
| JP (2) | JP6745726B2 (enExample) |
| KR (1) | KR102418167B1 (enExample) |
| CN (1) | CN106470991B (enExample) |
| AU (1) | AU2015239112C1 (enExample) |
| CA (1) | CA2943373C (enExample) |
| CL (1) | CL2016002508A1 (enExample) |
| CY (2) | CY1120454T1 (enExample) |
| DK (2) | DK3388064T3 (enExample) |
| EA (2) | EA035866B1 (enExample) |
| ES (2) | ES2872335T3 (enExample) |
| HR (2) | HRP20180983T1 (enExample) |
| HU (2) | HUE055351T2 (enExample) |
| IL (1) | IL248037B (enExample) |
| LT (2) | LT3388064T (enExample) |
| MX (1) | MX373234B (enExample) |
| NZ (1) | NZ725492A (enExample) |
| PL (2) | PL3388064T3 (enExample) |
| PT (2) | PT3388064T (enExample) |
| SG (1) | SG11201608218QA (enExample) |
| SI (2) | SI3125888T1 (enExample) |
| WO (1) | WO2015150476A1 (enExample) |
| ZA (1) | ZA201607286B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CA2941562C (en) | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| WO2015109037A1 (en) | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| LT3388064T (lt) * | 2014-04-02 | 2021-05-25 | Minoryx Therapeutics S.L. | 2,4-tiazolidindiono dariniai centrinės nervų sistemos sutrikimų gydyme |
| US11938122B2 (en) * | 2016-12-01 | 2024-03-26 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease |
| PT3559010T (pt) | 2016-12-23 | 2022-09-01 | Minoryx Therapeutics S L | Processo para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidinadiona e seus sais |
| MX2020013181A (es) * | 2018-06-06 | 2021-02-26 | Minoryx Therapeutics S L | Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona. |
| HRP20250591T1 (hr) * | 2018-06-06 | 2025-07-04 | Minoryx Therapeutics S.L. | 5‑[[4‑[2‑[5‑(1‑hidroksietil)piridin‑2‑il]etoksi]fenil]metil]‑1,3‑tiazolidin‑2,4‑dion i njegove soli, namijenjen upotrebi u liječenju mitohondrijskih bolesti |
| WO2019234690A1 (en) * | 2018-06-06 | 2019-12-12 | Minoryx Therapeutics S.L. | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts |
| MX2022013021A (es) | 2020-04-30 | 2023-01-16 | Minoryx Therapeutics S L | Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
| EP4642456A1 (en) | 2022-12-28 | 2025-11-05 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| AU2024268104A1 (en) | 2023-05-09 | 2025-11-27 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0579733B1 (en) * | 1991-04-11 | 2001-06-20 | PHARMACIA & UPJOHN COMPANY | Thiazolidinedione derivatives, production and use thereof |
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| WO1993022445A1 (en) * | 1992-05-05 | 1993-11-11 | The Upjohn Company | A process for producing pioglitazone metabolite |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| ATE319449T1 (de) | 2001-12-21 | 2006-03-15 | Smithkline Beecham Corp | Dosierschema für ppar-gamma-aktivatoren |
| US8993773B2 (en) | 2002-07-16 | 2015-03-31 | Cadila Healthcare Limited | Process to prepare pioglitazone via several novel intermediates |
| AU2003254146A1 (en) * | 2003-07-24 | 2005-03-07 | Case Western Reserve University | Methods for the treatment of parkinson's disease |
| ES2654908T3 (es) * | 2006-03-16 | 2018-02-15 | Metabolic Solutions Development Company Llc | Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| EP3202401B1 (en) * | 2009-12-15 | 2019-10-23 | Cirius Therapeutics, Inc. | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| WO2013040419A1 (en) * | 2011-09-14 | 2013-03-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US8865747B2 (en) | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20140178456A1 (en) | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| CA2941562C (en) * | 2013-03-14 | 2021-09-21 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| WO2015109037A1 (en) | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| LT3388064T (lt) * | 2014-04-02 | 2021-05-25 | Minoryx Therapeutics S.L. | 2,4-tiazolidindiono dariniai centrinės nervų sistemos sutrikimų gydyme |
-
2015
- 2015-04-01 LT LTEP18173541.6T patent/LT3388064T/lt unknown
- 2015-04-01 LT LTEP15713499.0T patent/LT3125888T/lt unknown
- 2015-04-01 ES ES18173541T patent/ES2872335T3/es active Active
- 2015-04-01 KR KR1020167030649A patent/KR102418167B1/ko active Active
- 2015-04-01 NZ NZ725492A patent/NZ725492A/en unknown
- 2015-04-01 EP EP18173541.6A patent/EP3388064B1/en active Active
- 2015-04-01 HU HUE18173541A patent/HUE055351T2/hu unknown
- 2015-04-01 JP JP2016560727A patent/JP6745726B2/ja active Active
- 2015-04-01 EA EA201691997A patent/EA035866B1/ru unknown
- 2015-04-01 DK DK18173541.6T patent/DK3388064T3/da active
- 2015-04-01 EP EP15713499.0A patent/EP3125888B1/en active Active
- 2015-04-01 SI SI201530325T patent/SI3125888T1/en unknown
- 2015-04-01 SG SG11201608218QA patent/SG11201608218QA/en unknown
- 2015-04-01 CA CA2943373A patent/CA2943373C/en active Active
- 2015-04-01 SI SI201531591T patent/SI3388064T1/sl unknown
- 2015-04-01 DK DK15713499.0T patent/DK3125888T3/en active
- 2015-04-01 AU AU2015239112A patent/AU2015239112C1/en active Active
- 2015-04-01 HR HRP20180983TT patent/HRP20180983T1/hr unknown
- 2015-04-01 PT PT181735416T patent/PT3388064T/pt unknown
- 2015-04-01 PT PT157134990T patent/PT3125888T/pt unknown
- 2015-04-01 CN CN201580018404.6A patent/CN106470991B/zh active Active
- 2015-04-01 PL PL18173541T patent/PL3388064T3/pl unknown
- 2015-04-01 HU HUE15713499A patent/HUE039555T2/hu unknown
- 2015-04-01 ES ES15713499.0T patent/ES2678046T3/es active Active
- 2015-04-01 MX MX2016012687A patent/MX373234B/es active IP Right Grant
- 2015-04-01 WO PCT/EP2015/057224 patent/WO2015150476A1/en not_active Ceased
- 2015-04-01 PL PL15713499T patent/PL3125888T3/pl unknown
- 2015-04-01 EA EA202091120A patent/EA202091120A3/ru unknown
-
2016
- 2016-05-05 US US15/147,484 patent/US9782395B2/en active Active
- 2016-09-26 IL IL248037A patent/IL248037B/en active IP Right Grant
- 2016-10-03 CL CL2016002508A patent/CL2016002508A1/es unknown
- 2016-10-21 ZA ZA2016/07286A patent/ZA201607286B/en unknown
-
2017
- 2017-10-05 US US15/725,950 patent/US10179126B2/en active Active
-
2018
- 2018-07-23 CY CY20181100765T patent/CY1120454T1/el unknown
- 2018-12-13 US US16/218,829 patent/US20190255032A1/en not_active Abandoned
-
2020
- 2020-05-07 JP JP2020081949A patent/JP2020117539A/ja active Pending
-
2021
- 2021-03-30 HR HRP20210518TT patent/HRP20210518T1/hr unknown
- 2021-04-27 CY CY20211100363T patent/CY1124088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3125888T1 (en) | 2,4-TIAZOLIDINDION DERIVATIVES FOR TREATMENT OF CENTRAL STYLE SYSTEM DISEASE | |
| JP2017511339A5 (enExample) | ||
| US20080153811A1 (en) | Methods of Treating Cognitive Impairment and Dementia | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| HRP20190857T1 (hr) | Inhibitori glikozidaze | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| SI2935307T1 (en) | Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures | |
| HRP20210158T1 (hr) | Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku | |
| MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
| PH12012501692A1 (en) | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions | |
| JP2016534063A5 (enExample) | ||
| JO3377B1 (ar) | مشتقات بيريدينيل وبيريدينيل مندمج | |
| TN2016000014A1 (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| MX370141B (es) | Profármacos que comprenden un conjugado de ácido hialurónico enlazador agonista dual de glp-1/glucagón. | |
| MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| JP2017505293A5 (enExample) | ||
| TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
| JP2016503785A5 (enExample) | ||
| PH12014502750A1 (en) | Heteroaromatic methyl cyclic amine derivative | |
| MY183111A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| MA38854B1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| JP2018531993A5 (enExample) | ||
| NZ611529A (en) | Glucagon receptor modulators | |
| HRP20170564T1 (hr) | Derivati aminociklobutana, metoda njihove priprave i njihova upotreba za lijekove |